| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
Aiming at cure of leukemia, we are developing a novel cellular immunotherapy using genetically modified T lymphocytes to express leukemia antigen specific T-cell receptor(TCR) which can recognize leukemia stem cells(LSCs). In this study, we have demonstrated the clinical feasibility of two therapeutic options targeting Wilms' tumor gene product 1(WT1) and Aurora kinase A(AURKA), and the usefulness of a novel TCR gene expression vector(siTCR vector) which simultaneously encodes silencers for endogenous TCRs. Currently, this on-going study using a xenografted NOG mouse model are accumulating positive lines of evidence that adoptively transferred LSC-specific CTLs can prohibit leukemia progression in vivo.
|
